Evaluation of Estrogen Dependency of Human Breast Cancers : II. Clinical evaluation of tamoxifen in advanced primary and recurrent breast cancer

ヒト乳癌におけるエストロゲン依存性の検討 : Ⅱ. 進行又は再発乳癌に対するタモキシフェンの臨床的評価

Nishiki Masayuki

Yamane Motoi

Amano Kuniki

Yasuda Katsuki

Okumichi Tsuneo

Ezaki Haruo

Hiroshima Journal of Medical Sciences

[PISSN] 0018-2052

[EISSN] 2433-7668

[NCID] AA00664312

An antiestrogen (tamoxifen) was given to 17 patients with advanced breast cancer (both recurrent and primary cancers) during a period from June 1981 to September 1983. The response rate to the antiestrogen was 47.8% (8/17). Sixty percent (6/10) of patients with estrogen receptor positive (ER +) responded, compared with 16.7% (1/6) of patients with estrogen receptor negative (ER －). Forty percent of patients with soft tissue/lymph nodes involvement responded, compared with 27.2% in patients with bone metastasis, and 25.0% in patients with visceral involvement. Postmenopausal patients responded more than premenopausal ones. In recurrent cases, the response rate increased with the prolongation of disease free interval.

Eight out of 17 patients are still alive, and the longest survival case has been in a condition of partial response for 23 months so far. The mean survival period in 9 deaths was 13±9 months, with longest 32 months.

As shown here, some patients with advanced breast cancer respond very well to the therapy. From these results, we think the tamoxifen-containing endocrinotherapy in combination with chemotherapy is effective in treatment of · advanced cancer and its active application may enable patients to live longer in the rehabilitated situation.

Breast cancer

Antiestrogens

Tamoxifen

医学 [ 490 ]

英語

Hiroshima University School of Medicine

[ISSN] 0018-2052

[NCID] AA00664312

[PMID] 6480380